121 patents
Page 4 of 7
Utility
Treatment of Schizophrenia
21 Oct 21
Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions.
Mihael H. Polymeropoulos
Filed: 28 Jun 21
Utility
Cancer Treatment
21 Oct 21
The invention relates generally to the treatment of cancer.
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Filed: 28 Jun 21
Utility
Method of treatment
12 Oct 21
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions.
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Filed: 25 Feb 20
Utility
Method of Treatment
30 Sep 21
Embodiments of the invention relate generally to increasing adult height in individuals with no light perception (NLP).
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 13 Apr 21
Utility
Depot Administration of Iloperidone
23 Sep 21
Methods of preparing and administering an injectable depot formulation of crystalline iloperidone are disclosed herein.
Mihael H. Polymeropoulos
Filed: 4 Dec 19
Utility
Prediction of Sleep Parameter and Response to Sleep-inducing Compound Based on PER3 VNTR Genotype
9 Sep 21
The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
Christian N. Lavedan, Mihael H. Polymeropoulos, Gunther P. Birznieks
Filed: 21 May 21
Utility
Treatment of circadian rhythm disorders
17 Aug 21
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 4 Jan 19
Utility
Cancer treatment
3 Aug 21
The invention relates generally to the treatment of cancer.
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Filed: 18 Mar 19
Utility
Method of Treatment with Tradipitant
29 Jul 21
Methods of treating an individual experiencing or at risk of experiencing an undesired consequence of opioid use, and of treating an individual who is experiencing or at risk of experiencing a craving for an opioid, as well as the use of the NK-1 receptor antagonist, tradipitant, in the treatment of such an individual are disclosed herein.
Mihael H. Polymeropoulos, Gunther Birznieks, Sharon Walsh
Filed: 6 Jun 19
Utility
Treatment of schizophrenia
27 Jul 21
Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions.
Mihael H. Polymeropoulos
Filed: 12 Dec 16
Utility
Liquid Tasimelteon Formulations and Methods of Use Thereof
15 Jul 21
Liquid suspensions of tasimelteon and methods for their use.
Deepak Phadke, Mihael Polymeropoulos
Filed: 29 Mar 21
Utility
Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
13 Jul 21
The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
Christian Lavedan, Mihael H. Polymeropoulos, Gunther Birznieks
Filed: 12 Sep 08
Utility
Treatment of Circadian Rhythm Disorders
8 Jul 21
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 19 Mar 21
Utility
Methods for the Administration of Iloperidone
24 Jun 21
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Curt D. Wolfgang, Mihael H. Polymeropoulos
Filed: 3 Mar 21
Utility
Liquid Tasimelteon Formulations and Methods of Use Thereof
17 Jun 21
Liquid suspensions of tasimelteon and methods for their use.
Deepak Phadke, Mihael Polymeropoulos
Filed: 11 Dec 20
Utility
Treatment of Circadian Rhythm Disorders
3 Jun 21
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 8 Feb 21
Utility
Depot Administration of Iloperidone
3 Jun 21
Methods of preparing and administering an injectable depot formulation of crystalline iloperidone are disclosed herein.
Mihael H. Polymeropoulos
Filed: 12 Feb 21
Utility
Method of treatment
25 May 21
Embodiments of the invention relate generally to increasing adult height in individuals with no light perception (NLP).
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 15 Dec 16
Utility
Treatment of Circadian Rhythm Disorders
6 May 21
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 15 Jan 21
Utility
Iloperidone for the treatment of schizophrenia
27 Apr 21
Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof.
Mihael H. Polymeropoulos, Curt D. Wolfgang
Filed: 6 Sep 19